Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Axsome Therapeutics dosed the first patient in the SUMMIT Phase 3 trial evaluating AXS-05 as a treatment for smoking cessation. The randomized, double-blind study will assess the efficacy and safety of AXS-05 compared to bupropion and placebo over a 12-week treatment period. This expansion targets a market of 34 million U.S.
Key figures
- Drug Name
- AXS-05
- Phase Of Trial
- Phase 3
- Patent expiry
- at least 2043
- Us adult smokers
- 34 million
- Annual smoking cost
- $300 billion
- Treatment duration weeks
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.